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ABSTRACT 
Tumours in the central nervous system are accountable for the 
majority of cancer-related deaths in children. Glioblastoma multiforme, 
one of the deadliest of the central nervous system tumours, is partly 
driven by glioma stem cells. The generation and maintenance of these 
cells are orchestrated by complex genetic and epigenetic 
mechanisms.  
This thesis investigates the role of two epigenetic players, miRNAs 
and DNA methylation, as well as the involvement of exosomes in 
paediatric glioma stem cells. The first study profiles the miRNA 
content of these cells and compares it to normal neural stem cells. 
Furthermore, the miRNA content of the exosomes secreted by glioma 
stem cells and its effect on normal stem cells is determined. The 
second study investigates how specific miRNAs are regulated and 
how they could potentially influence glioma stem cells’ response to the 
chemotherapeutic agent temozolomide. 
These studies provide new insights into the multifaceted epigenetic 
regulation of glioma stem cells. The gained knowledge could lead to a 
better understanding of the biological processes behind brain tumours.  
Keywords: epigenetics, microRNA, DNA methylation, exosomes, 
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SAMMANFATTNING PÅ SVENSKA 
De flesta cancerrelaterade dödsfall hos barn och ungdomar orsakas 
av tumörer i det centrala nervsystemet. Glioblastom är en av det 
centrala nervsystemets dödligaste cancerformer, och den drivs delvis 
av speciella gliomstamceller; celler som kan ge upphov till nya 
tumörceller. Gliomstamcellernas uppkomst och fortlevnad styrs av 
komplexa genetiska och epigenetiska mekanismer. Medan genetik 
studerar hur arvsmassan är uppbyggd är epigenetik den vetenskap 
som berör regleringen av arvsmassan, alltså de processer som styr 
när och var specifika gener ska uttryckas och bilda protein, trots 
samma DNA sekvens.  
I den här avhandlingen undersöks rollen av två epigenetiska 
processer, miRNA och DNA metylering, liksom rollen av exosomer 
(små membranförsedda vesiklar som kan knoppas av från celler), i 
gliomstamceller från barn. Den första studien studerar miRNA-
innehållet i gliomstamceller jämfört med friska neurala stamceller. 
Vidare bestäms innehållet av miRNA i de exosomer som utsöndras 
från gliomstamcellerna, och vilken effekt detta har på normala 
stamceller. I den andra studien undersöks hur specifika miRNA 
regleras och hur de potentiellt kan påverka gliomstamcellernas svar 
på cytostatikumet temozolomide. 
Sammantaget ger dessa studier nya insikter i den mångfacetterade 
epigenetiska regleringen av gliomstamceller. Sådan kunskap kan leda 
till en bättre förståelse av de biologiska processer som ligger bakom 
hjärntumörer. 
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 “One never notices what has been done;  
one can only see what remains to be done.” 
Marie Curie 
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1.1 Genetics 
The hereditary material of an organism is encoded in the most 
fascinating and elegant macromolecule, deoxyribonucleic acid (DNA), 
located inside the nucleus of each cell. Prior to the discovery of the 
structure and principal functions of the DNA molecule by Watson and 
Crick in the fifties [1], few theories existed on the hereditary 
mechanism. The presence of hereditary material that passed between 
generations was first described hundred years before by Gregor 
Mendel [2].  
Genes are traditionally defined as specific sequences of DNA that 
code for different bio-macromolecules, proteins with diverse cellular 
functions [3]. The term “gene” was first mentioned in 1905 by Wilhelm 
Johannsen who also coined the term “genotype” as “the sum total of 
all the genes in a gamete or in a zygote” [4]. A genome consists of all 
the genetic material of an organism, and the field studying this is 
called genomics. Currently, 19,000 protein coding genes are known 
[5], while the rest of the genome consists of so called ‘non-coding 
DNA’ such as introns, retrotransposons, and regions that encode non-
coding ribonucleic acid (RNA) [6, 7]. 
The DNA molecule is made up by four nucleotide bases: adenine (A), 
cytosine (C), guanine (G), and thymine (T) paired in a double helix. 
These almost two metre long strings of sequences are folded and 
wrapped around the four core histone proteins: H2A, H2B, H3, and H4 
[8, 9]. Further packing of this structure will result in higher order 
chromatin and finally give rise to the most condensed state, 
chromosomes, only visible at cell division (illustrated in Figure 1).  
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Figure 1. Chromatin organisation. The DNA double helix is wrapped 
around histones in a structure named nucleosome. Further packing will result 
in a more compact form termed chromatin. The final and most condensed 
state is the chromosome.  
Transcription is the step in which the DNA is copied into RNA which 
later can be translated into chains of amino acid residues producing 
functional proteins [10]. Genes can also code for RNA molecules that 
never give rise to proteins, but are functional themselves, often with 
regulating roles. The process of synthesising functional molecules 
from genes is termed gene expression. RNA molecules, similar to 
DNA, are composed of four nucleotide bases: A, G, C, and uracil (U). 
However, RNA is often single stranded and does not have the 
complex secondary structure of DNA. 
1.2. Epigenetics 
1.2.1. Epigenetic mechanisms 
The term ‘epigenetics’ was coined by Conrad Hal Waddington in 1946 
to describe how genes interact with the environment, sometimes also 
changing the characteristics of the organism [11]. A more 
contemporary definition of epigenetics refers to changes in 
characteristics or gene expression that do not involve alterations in the 
DNA sequence [12]. Numerous epigenetic modifications exist, 
however the most studied ones are DNA methylation and histone 
modifications [13, 14]. While DNA methylation most often occurs 
through the addition of a methyl group to a cytosine residue in the 5th 
position, modifications can also occur on the N-terminal of the histone 
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tails; such modifications are acetylation, methylation, phosphorylation, 
sumoylation, ubiquitination, and ADP ribosylation [9, 14]. Currently, 
other epigenetic modifications such as posttranscriptional 
modifications are also gaining interest [14, 15]. These include 
modifications at the RNA level [16], as well as the involvement of non-
coding RNAs in regulation of gene expression [17, 18].  
Figure 2. Epigenetic modifications. Red, green, and blue circles indicate 
histone tail modifications, yellow circles indicate DNA methylation. Other 
epigenetic modifications such as posttranscriptional modifications are 
performed for example through miRNA silencing that will lead to gene 
expression changes.  
1.2.2. DNA methylation 
DNA methylation occurs mainly on a cytosine that is followed by a 
guanine (CpG dinucleotide) through the addition of a methyl group by 
enzymes termed DNA methyltransferases (DNMTs) [14, 19, 20]. In 
this process, the DNMTs use S-adenosyl methionine as the methyl 
donor.  
There are approximately 28,000 CpG islands in the human genome 
[21]. They often have regulatory roles, and at least half of them can be 
found in promoter regions of genes [14, 22], while others are located 
in gene bodies [14, 23]. In general, CpG island methylation in 
promoter regions has been linked to transcriptional repression [19, 24, 
25] (Figure 3) through physically hindering the binding of proteins
required for transcription to the DNA sequence.
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Figure 3. DNA methylation and gene expression. Gene expression may 
be regulated through the presence or absence of DNA methylation at 
promoter regions. Adapted from [26]. 
Methylated DNA can also be bound by methyl-CpG-binding domain 
proteins (MBDs) [27, 28]. Those will engage further chromatin and 
histone modifying proteins, thus causing a compact form of chromatin 
that is not accessible for transcription. This type of chromatin is called 
heterochromatin.     
DNA methylation in the gene body can be found in highly transcribed 
genes, and this is conserved between plants and animals [29]. DNA 
methylation in the gene body is known to prevent aberrant 
transcription initiation [30].  
Methyl groups can also be removed from the DNA, in a manner that 
can be either passive or active. Passive DNA demethylation is a result 
of improper re-establishment of methylation marks after DNA 
replication, while active demethylation is catalysed by different 
enzymes [31, 32]. Some of these enzymes are known as ten-eleven 
translocation enzymes (TETs) which can oxidize the methyl group, 
thus giving rise to 5-hydroxymethylcytosine [33].  
DNA methylation plays an important role in embryonic development 
[34, 35]. Experimentally induced mutations in DNA methyltransferase 
genes have been shown to decrease the levels of DNA methylation in 
mouse embryonic stem cells without having an effect on the viability or 
proliferation of the cells. However, in vivo experiments showed 
abnormal development or death in embryos [35]. DNA methylation is 
also involved in cellular differentiation [36]. Experimental evidence has 
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identified DNMT1 as responsible for the maintenance of DNA 
methylation patterns during cell replication [35, 37]. The role of DNA 
methylation in cancer has been investigated since the early 1980’s, 
when decreased methylation was detected in tumour tissues from 
patients with colorectal adenocarcinoma and small cell carcinoma of 
the lung compared to normal tissue [38]. Since then, many tumour 
suppressor genes have been found to be methylated in their 
promoters in different tumours [25], for example CDKN2A in head and 
neck carcinoma, gliomas, breast, prostate, and renal cancer [39, 40], 
and BRCA1 in breast carcinoma [41]. 
1.2.3. MicroRNAs 
A considerable part of the human genome consists of genes that are 
not coding for proteins, but for RNAs with regulatory roles.  
These RNAs are termed non-coding RNAs and are very diverse, but 
often have significant roles in cellular processes by regulating gene 
expression, translation, RNA splicing, and DNA replication [42]. They 
are important for proper cell functioning and have been found to be 
dysregulated in different diseases [43]. Based on their size, two main 
categories exist: long non-coding RNAs (lncRNAs) and short non-
coding RNAs.  
MicroRNAs (miRNAs) are part of the short non-coding RNA group 
(they are approximately 22 nucleotides long in their mature form). 
They act as gene expression regulators through their complementary 
sequences to mRNAs, mostly in the 3’UTR and less commonly in the 
5’UTR region of the target RNA [44]. One miRNA can have several 
hundred of target mRNAs; even when the sequences are only partially 
complementary, recognition is possible. However, most often there is 
a perfect complementarity between the miRNA “seed” sequence and 
the target mRNA sequence. The miRNA seed sequence is a region 
found between the second and seventh nucleotide on the 5’ end of the 
mature miRNA [45, 46].  
MiRNA genes are located in the introns or exons of other protein 
coding genes and are transcribed in parallel with those, but can also 
Epigenetics of paediatric glioma stem cells; focusing on exosomes, miRNAs and DNA 
methylation 
6 
be located between coding regions (intergenic miRNAs) [47]. The 
miRNA genes are most often transcribed by RNA Polymerase II, and 
less commonly by RNA Polymerase III, in a long (several hundreds of 
nucleotides) stem-loop shape termed pri-miRNA. This double 
stranded hairpin shape undergoes processing by the Microprocessor 
complex where it is recognized by the nuclear protein DGCR8, which 
then associates with Drosha that cuts the RNA. This will result in a 
pre-miRNA form that is exported from the nucleus through Exportin-5 
into the cytoplasm where it is further processed by the RNase III 
enzyme Dicer. The processing by Dicer will result in the removal of the 
loop which joins the 3’ and 5’ arms, resulting in an imperfect miRNA 
duplex. Only one of the strands is incorporated into the so-called RISC 
complex. This complex has Argonaute proteins (Ago) as its catalytic 
centre, where the mature miRNA and its target mRNA will interact [48] 
(Figure 4).  
 MiRNAs biogenesis and function. MiRNA genes are transcribed Figure 4.
by RNA Pol in pri-miRNAs that are further processed into pre-miRNAs. These 
are transported from the nucleus to cytoplasm and further processed by 
Dicer. Only one strand is incorporated in RISC complex where mature 
miRNAs interact with their target mRNA leading to translational repression or 
degradation of the target RNA. Adapted from [49]. 
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There are approximately 2,600 different types of mature miRNAs in 
the human body. The miRNAs are named through a system where the 
first part specifies the organism (hsa if human) and the next part 
reveals if it is a mature miRNA (miR). Next follows a sequence of 
numbers that are specific for each miRNA, indicating the order in 
which they were named (and most likely discovered). In addition, the 
miRNA can be assigned either 3p or 5p mainly depending on from 
which precursor it is originating. MiRNAs with identical mature 
sequences, but with distinct precursor sequences, contain a letter (a, 
b, c etc.) after the miRNA number as described in miRBase 
nomenclature guide [50-52]. MiRNA clusters are formed by miRNAs 
that are less than 3,000 nucleotides away from each other, while 
miRNA families consist of miRNAs with identical ancestors in the 
phylogenetic tree and have similar biological functions [53].  
The most often described function of miRNAs is the repression of their 
target genes, however up-regulation of genes also occurs [54]. 
Repression can be achieved either by inhibiting the translation of the 
target gene to protein or by direct degradation of the mRNA [55].  
MiRNAs are involved in the regulation of vast cellular processes. They 
have an important role in embryogenesis [56, 57]; for example miR-
430 that is involved in zebrafish brain morphogenesis [58]. MiRNAs 
can also regulate cell differentiation and cell fate [59]. Up-regulation of 
the miR-290-295 cluster was detected in murine embryonal stem cells 
[60] while the miR-302, miR-17, and miR-106a clusters are highly
expressed in human embryonal stem cells [61]. MiRNA expression
can be dysregulated in different types of cancers such as for example
the members of the miR-17∼92 cluster, which are considered to have
oncogenic functions and are up-regulated in leukaemia, lymphoma,
and glioma [62, 63]. Furthermore, miRNAs can have a role in
regulation of DNA methylation by targeting components of the DNA
methylation machinery. For example, miRNAs from the miR-290-295
cluster target DNMT genes in mouse embryonic stem cells [64]. The
expression of miRNAs can also be silenced by DNA methylation in the
corresponding genomic sequence, which has been described for
example for miR-34b-3p and -5p in neuroblastoma cell lines [65].
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Another posttranscriptional regulator of gene expression is small 
interfering RNA (siRNA). This is a class of small RNAs (20-25 base 
pairs), similar to miRNAs in structure and function. SiRNAs are 
broadly used in gene silencing studies, since they easily can be 
introduced into cells and have high target specificity through their full 
complementarity to the mRNA [66].  
1.3. Cancer genetics and epigenetics 
1.3.1. Cancer 
The concept of cancer covers a group of diseases that are the most 
common sources of death caused by health conditions. Cancer 
involves abnormal cell growth that has the potential to spread to 
different parts of the body in a way that will affect the normal 
functioning of the organism, ultimately resulting in death. There are 
more than 100 types of cancers that can affect humans and these can 
arise in any parts of the body [67, 68]. 
Nowadays, there are several treatment options for different types of 
cancers, and the survival rates are much better than in previous 
decades. However, a successful treatment highly depends on the type 
of cancer and the time of diagnosis. Despite the great advances in the 
field of cancer treatment, still full elimination of cancer, a good quality 
of life during and after treatment, and a long survival time are hard to 
achieve. Most treatment regimens involve surgical removal of the 
tumour, treatment with chemotherapeutical drugs, and ionizing 
radiation. New treatments have been introduced or are investigated, 
such as the use of immunotherapies and epigenetic drugs for specific 
diagnoses [69-71]. 
Cancer can affect all age categories; however some types of cancer 
increase in frequency with age. Breast and prostate cancer are among 
the most common cancers in adults while in children cancers in the 
blood, brain, and lymph nodes are the most common [68, 72]. Certain 
cancers are due to genetic aberrations and epigenetic modifications 
caused by environmental factors, such as an unhealthy life style 
(smoking, dietary habits, and lack of physical activities) [73] or 
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exposure to damaging factors (chemicals, radiation and infections). 
The main cause of lung cancer is attributed to smoking [74] while 
dietary habits have been associated with the occurrence of gastro-
intestinal cancers [75]. Some cancer forms have been linked to the 
effects of hormones (insulin-like growth factors) [76] or associated with 
autoimmune diseases (celiac disease and Crohn’s disease) [77, 78]. A 
smaller part of cancers can have hereditary origins [79, 80].   
1.3.2. Genetics and epigenetics of cancer 
The presence of mutated genes in cancer cells is common. Two main 
groups of genes are specifically mutated in cancer cells; oncogenes 
and tumour suppressors. Proto-oncogenes can be activated into 
oncogenes by mutations, amplifications, and translocations which can 
promote transformation of cells [81-83]. The role of tumour 
suppressors is to inhibit abnormal cell proliferation thereby protecting 
cells from cancer transformation. However, loss of function of tumour 
suppressor genes can result in malignant changes [84]. MYC, ERBB2, 
BRAF, KRAS, and EGFR are some of the most well-known 
oncogenes while RB, PTEN, and TP53 are considered tumour 
suppressors [85].  
In the classical view of cancer development, genetic alterations have 
been considered the driving forces. In the modern view, it is known 
that beside genetic modifications, also epigenetic alterations play a 
major role in cancer formation, progression, and even relapse through 
their effect on gene expression regulation [86]. Such epigenetic 
modifications are DNA methylation, histone modifications, and 
posttranscriptional modifications [87, 88].   
1.4. Cancer stem cells 
1.4.1. Stem cells and cancer stem cells 
Cancer stem cells (CSCs) have common features with stem cells 
(SCs) [89]. Both SCs and CSCs have the ability to differentiate into 
multiple types of cells and also to divide and maintain stemness (self-
renewal) [90]. The regulation of self-renewability in both SCs and 
CSCs involves signalling pathways such as BMI-1, Notch, MAPK, 
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Sonic Hedgehog, and Wnt. Furthermore, they have the capacity for 
increased life span through extended telomerase activity, stimulation 
of angiogenesis, and the ability to secrete growth factors [91]. 
CSCs have been identified in several tumour forms, including 
leukaemia [92], brain [93], breast [94], colon [95], and melanoma [96].  
For the identification of CSCs, several different surface markers are 
used such as for example CD24 for ovarian cancer stem cells [97], 
CD33+ and CD38- for acute myeloid leukaemia [92], while for brain 
CSCs CD44 and CD133 are the most commonly used [91, 98].  
In case of the high-grade brain tumour Glioblastoma Multiforme 
(GBM) the CSCs can be called glioma stem cells (GSCs). Isolation of 
the GSC population can be done by flow cytometry where cells are 
sorted by the surface antigen CD133 [98]. However, the validity of 
using CD133 as a universal marker for GSCs has been questioned 
[99, 100] and other approaches include enriching the GSCs by 
culturing the cells under stem cell conditions [101, 102]. Other 
commonly used experiments for validating GSC features are to test 
the cells’ neurosphere formation abilities [103] and their tumour 
initiating properties in animal models [102, 104].  
CSCs have specific properties that normal SCs do not exhibit. CSCs 
are considered to be the driving forces behind many tumours due to 
their tumour initiating properties, as well as due to their abilities of 
indefinite self-renewal, migration, and aberrant differentiation [91]. 
They also play a major role in cancer relapses as a result of their 
ability to escape traditional treatments [98].  
1.4.2. Cell cycle and dormancy 
The ability of CSCs to resist treatments might be due to that these 
cells, as in general all SCs, have a slower proliferation rate than 
rapidly dividing cancer cells [90]. Several studies have identified a 
stage in cancer progression where cells stop dividing but survive in a 
so-called dormant (quiescence) state when the environmental 
conditions are not beneficial for proliferation [105]. Cells that enter this 
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quiescence state are found in cell cycle arrest in the G0-G1 phase. 
The cell cycle in human cells consists of three phases; interphase, 
mitosis and cytokinesis. The interphase, when the cell is preparing for 
division by taking up nutrients, can be divided further into three 
phases: Gap 1 (G1) when the cell grows in size, the S phase when the 
DNA replication takes place, and Gap 2 (G2) when the cell grows 
further preparing for mitosis. During the G1 phase the cell has the 
option for three routes: to continue the cell cycle by entering the S 
phase, to stop the cell cycle by entering the G0 phase for 
differentiation, or to undergo cell cycle arrest in the G1 phase that will 
lead to either entering the G0 phase or re-entering the cell cycle. The 
mitotic phase (M phase) is a short but complex time in the cell cycle 
that consists of nuclear division. This phase is followed by cytokinesis, 
in which the cell division is finalised by the division of nuclei, 
cytoplasm, organelles, and cell membrane resulting in two daughter 
cells that are genetically identical to each other and to their parental 
cell (reviewed in [106]). The main phases of the cell cycle are showed 
in Figure 5.  
 Cell cycle phases. In G1 cells grow in size and can enter either Figure 5.
G0 phase or continue with S phase when DNA replication takes place. During 
G2 phase cells grow further preparing for mitosis: M phase, resulting in two 
daughter cells.  
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The cell cycle is regulated strictly by different molecules (cyclins and 
cyclin-dependent kinases) to ensure proper cell division. During the 
cell cycle phases, several checkpoint control mechanisms ensure 
proper cell cycle progression. When a dysregulation occurs and 
remains uncorrected, this could lead to tumour formation for example 
through uncontrollable cell division. During increased cell proliferation, 
dysregulation of several cell cycle genes were detected in many 
different types of cancers [107]. Furthermore, typical gene expression 
changes were described in case of cancer cells that stop the cell cycle 
and enter into a dormant state [108]. Some of these genes were 
identified in slow proliferating tumours and related to the S phase of 
the cell cycle, such as CDT1 and PCNA [109, 110], while other genes 
such as TGFB2 and THBS1 were found to have a higher expression 
in dormant tumour cells than in fast proliferating cancer cells [108]. 
Common traits exist between dormant tumour cells and CSCs, 
however very few studies investigated if CSCs can enter a dormant 
state [111]. These studies suggest that CSC niches can be formed 
also by a heterogeneous subpopulation, including a quiescent fraction 
[112, 113]. This raises the question of the existence of fast and slower 
proliferating cells in the CSC niche.  
1.4.3. Origins, genetics, and epigenetics of CSCs 
Several hypotheses exist that try to explain the origins of CSCs. 
The so called “tumour hierarchy” hypothesis suggests that a tumour 
niche is built up by heterogeneous cells, which all might have the 
same or very similar mutations, but present different phenotypes 
[114]. Simply described, this niche is formed by cancer cells and 
CSCs. According to this hypothesis (also known as the CSC model) 
the growth of a tumour and the disease progression are due to a small 
population of cells from the tumour niche, known as CSCs [89, 115]. 
This is possible since CSCs are capable of symmetric and asymmetric 
division while cancer cells divide symmetrically. Asymmetric division of 
CSCs will result in a cancer cell and a new CSC that can continue 
further with symmetric or asymmetric division (Figure 6). 
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 CSC division can be symmetric resulting in CSCs, and Figure 6.
asymmetric resulting in one CSC and one cancer cell (CC). Adapted from 
[116].  
Mathematical simulations showed that the fast proliferating cancer 
cells are at the periphery of a tumour niche and spatially inhibit the 
CSCs from the tumour periphery to the quiescence tumour part [116]. 
When the cancer cells from the outer periphery exhaust their 
proliferation potential, the CSCs from the core of the tumour can re-
enter a faster proliferation state and through asymmetrical division 
again repeating the previous dynamics or through symmetrical division 
produce new CSCs. These new CSCs can, through migration, form a 
spatially new tumour population as part of the “self-metastatic tumour 
progression” mechanism [116, 117].      
Another hypothesis claims that the occurrence of CSCs is due to 
mutations in the stem cell niche acquired during development that is 
later shared through cell division [118]. It was found that astrocyte-like 
neural stem cells (NSCs) with low level driver mutations, found in the 
subventricular zone, can migrate to different regions of the brain and 
induce high-grade gliomas [119]. 
An alternative theory associates CSCs with adult stem cells since 
these cells have a higher cell division rate and a long life span, 
features favourable for the accumulation of mutations leading to 
cancer occurrence [120]. It was shown that the risk of developing 
cancer during a life time is strongly correlated with the number of cell 
divisions. In tissues most of the cells are differentiated and have a 
short lifespan, which probably makes them unable to form tumours. 
However SCs have the capability of self-renewal and through this to 
maintain the tissue structure [121].  
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The de-differentiation theory claims that cells that acquire mutations 
could gain the ability to undergo a change that will lead them back to a 
stem-like state. This theory is supported by experimental evidence, for 
example the study in which oncogenes was found to induce 
dedifferentiation of neurons and astrocytes leading to tumour 
formation in mice [122].  
The generation and maintenance of CSCs are orchestrated by 
different epigenetic changes. Several pathways with roles in self-
renewal and differentiation of CSCs are affected by epigenetic 
mechanisms, such as the Sonic Hedgehog, Notch, Wnt/β-catenin, and 
TGF-β/BMP signalling pathways. One example is Wnt signalling 
activation by several transcription factors whose expression is 
regulated by their promoter H3K27me3 pattern in GSCs [123]. 
MiRNAs are also players in CSCs, for example let-7 that has low 
expression in breast CSCs and increase with differentiation. In vivo 
experiments showed that let-7 reduced tumour formation and 
metastasis, suggesting its role in self-renewal of CSCs [124].  
1.4.4. Therapy and CSCs 
Traditional cancer therapy involves the use of chemotherapeutical 
drugs with the aim to decrease cancer cell proliferation. Since CSCs 
are considered the driving force behind many tumours due to their 
exceptional therapy escaping features, several studies are 
investigating the possibilities of developing new types of drugs that will 
lead to more efficient therapies. As epigenetic mechanisms play a 
major role in CSC biology, one group of new therapies aim to target 
different epigenetic players. The most studied epigenetic inhibitors are 
designed for HDACs and DNMTs [70, 125].  
1.5. Exosomes 
1.5.1. Exosomes biogenesis 
Cells release different types and sizes of extracellular vesicles (EVs) 
into their environment. The EVs, based on their size or release mode, 
can be classified into three main categories: apoptotic bodies (ABs), 
microvesicles (MVs), and exosomes. The ABs are the biggest in size, 
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with a diameter of 1,000-5,000 nm. They are released by cells that 
undergo apoptosis. The MVs have a size of 100-1,000 nm in diameter, 
and they are shed from the plasma membrane. The exosomes are the 
smallest extracellular vesicles with a size of 30-100 nm in diameter. 
They have an endocytic origin [126].  
Exosome formation starts by invagination of the cell membrane. This 
process will result in the formation of endosomes. The early 
endosomes mature into late endosomes. The inward budding of the 
endosomal membrane will form intra luminal vesicles (ILVs). Due to 
their morphological features, they are often named multivesicular 
bodies (MVBs) [127, 128]. The MVBs can fuse either with lysosomes 
for degradation, or with the plasma membrane of the cell to secrete 
the vesicles to the extracellular environment. The main steps of 
exosome biogenesis are graphically presented in Figure 7. 
 Exosomes biogenesis starts with the invagination of the cell Figure 7.
membrane, forming endosomes. The early endosomes mature into late 
endosomes which will lead to the formation of MVBs. The MVBs can fuse 
either with lysosomes and will be degraded or with the plasma membrane to 
release the vesicles to the extracellular environment. These released vesicles 
are termed: exosomes. Adapted from [128]. 
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1.5.2. Molecular composition of exosomes 
The first observation and description of the existence of small 
extracellular vesicles occurred in the 1980’s [129]; however, they have 
gained more attention in the last decade since the discovery of their 
molecular content [130]. All types of extracellular vesicles have a 
complex molecular content, which differ between the different types of 
vesicles [131]. EVs contain various sorts of proteins, such as annexins 
and tetraspanins, which also can be used as markers for EVs.  
During exosome formation, the endosome membrane in the ILV is 
enriched in tetraspanins such as CD9 and CD63 [127, 132]. The 
presence of endosomal sorting complexes (ESCRTs) required for 
transport is an important step in the exosome forming process  [133] 
and their lack can lead to reduced exosome release [134, 135]. Also, 
ESCRTs are essential for protein sorting in these processes [136]. 
Exosomes are enriched in several diverse molecules such as lipids, 
lipid rafts, adhesion molecules, signal transduction molecules, immune 
regulator molecules, heat-shock proteins, and cytoskeletal proteins 
[137, 138]. Some studies have described the presence of 
mitochondrial DNA (mtDNA) in exosomes released by cells such as 
astrocytes and glioblastoma cells [139]. Fragmented double-stranded 
DNA has also been found in exosomes [140], or attached to the 
exosome surface [141]. The presence of diverse RNA species in 
exosomes has been widely described in several studies; however little 
is known about how and why these RNAs are packed into the 
exosomes.  
Exosomes have a rich non-coding RNA repertoire alongside mRNAs 
[130, 131, 142]. Beside miRNAs, exosomes also contain long non-
coding RNAs, transfer RNA (tRNA), vault RNA, Y RNA, siRNA, 
circular RNA, and mitochondrial RNA. The enrichment of certain 
miRNAs and other RNA species in exosomes lead to the assumption 
of the existence of cargo sorting mechanisms. This would presume 
that sorting of specific RNAs into exosomes is actively regulated. Such 
a mechanism was described in a study where a Dicer deletion was 
found to lead to reduced miRNA content in exosomes compared to in 
cells [143]. Changes in miRNA and target gene levels in the cell can 
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also influence the sorting of RNA into exosomes [143]. Mechanisms 
and molecules that have been associated with RNA sorting 
mechanisms into exosomes include: a “zipcode-like” 25 nucleotide 
long sequence in the 3’UTR of the mRNAs enriched in EVs [144], 
KRAS-MEK signalling controlling Ago2 sorting to exosomes [145], and 
RNA binding proteins (RBPs) [146]. The RBPs identified to have a role 
in the sorting of small non-coding RNAs into exosomes are: the Y-box 
protein 1 (YBX1) [147, 148], and the heterogeneous nuclear 
ribonucleoprotein A2B1 (hnRNPA2B1) [149]. HnRNPA2B1 was found 
to be sumoylated in exosomes, a post-translational modification that 
controls protein binding to miRNAs by recognizing specific miRNA 
sequences termed “exo-motifs” [149]. The enrichment of exo-motifs 
containing miRNAs in exosomes was also found in Study I presented 
in this thesis [150].
1.5.3. Exosome release and up-take 
When cells release extracellular vesicles, these end up in the 
extracellular environment, and they can reach other parts of the body 
through the circulating body fluids.  
Exosome release by cells takes place through the fusion of MVBs with 
the plasma membrane, a mechanism that involves a variety of 
proteins [151]. MVB transport and docking to the plasma membrane is 
cortactin (which is an actin binding protein) dependent, and the 
presence or absence of this protein can increase or decrease 
exosome release [152]. Among the proteins associated with exosomal 
release are Rab GTPases [153, 154] and other small GTPases, 
SNARE proteins [155], and many more. 
EVs can be taken up by a variety of other cells in their nearest 
environment or by cells from distant body parts. In the beginning, most 
of these vesicles were considered as waste, but were later identified 
to have a role in cell to cell communication [156]. When the EVs are 
taken up by other cells, they can affect the receiver cells through their 
molecular content [130]. Exosomes dock at the plasma membrane of 
the cells where, based on their surface adhesion molecules (integrins 
and tetraspanins), the up-take fate is decided [156]. Apparently, the 
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up-take can also be dependent on the exosome size [157]. Exosome 
up-take can occur through two main processes: either the vesicle 
fuses with the plasma membrane, or it is taken up by the cell through 
endocytosis. Vesicles internalised through endocytosis will fuse with 
the membrane of an endocytic compartment or will be delivered to 
lysosomes for degradation. Through both up-take processes the 
vesicle content will be delivered into the cytosol or to the membrane of 
the receiver cell [156]. Exosome up-take by cells can be confirmed 
with fluorescence/confocal microscopy or flow cytometry methods 
where the vesicles are stained with dyes; PKH67, a fluorescent lipid 
membrane dye, being one of the many used for EV detection [158].  
1.5.4. Exosomes function 
The most frequently described function of EVs, including exosomes, is 
their role in cell to cell communication through their molecular content. 
These vesicles are implicated in the maintenance of normal 
physiological processes and can be involved in pathological 
processes.  
EVs can mediate immune modulation with immune activating or 
immunosuppressive effects [159]. Mature dendritic cells can release 
exosomes that activate T cells by binding to their receptors and induce 
an adaptive immune response [160]. One study also described that 
exosomes released from dendritic cells could eradicate tumours in a 
mouse model [161], while vesicles isolated from serum of oral cancer 
patients induced apoptosis of activated T lymphocytes [162] pointing 
towards an immunosuppressive role of these vesicles. 
EVs play an important role in the communication between brain cells 
as was demonstrated in a study where exosomes released by 
oligodendrocytes enhanced neuronal stress tolerance in neurons that 
had taken up these vesicles [163]. Furthermore, these exosomes 
promoted neuronal survival in a cerebral ischemia model, during 
oxygen-glucose deprivation [163].  
EVs are also associated with many different diseases, such as for 
example liver disease [164], neurodegenerative diseases [165], and 
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cancer [166]. In cancers, EVs can manipulate the tumour environment 
and facilitate metastasis [167, 168]. This was shown for gastric 
cancer, where mesenchymal stem cell (MSC) exosomes promoted 
cell growth and migration [169], and in glioblastoma cells where these 
vesicles promoted cell proliferation [142]. 
Extracellular vesicles can be detected in body fluids such as blood, 
serum [170], cerebrospinal fluid [171], urine [172], saliva [173], breast 
milk [174], seminal fluid [175], nasal lavage [176], and amniotic fluid 
[177]. The detection of EVs from body fluids can due to their molecular 
content be used in medicine as biomarkers of different diseases such 
as for example cancer [178]. Several studies suggested that these 
EVs are mirroring the molecular content of their source cell [142, 179] 
and therefore could be used as biomarkers that show a glimpse of the 
ongoing malfunctions of malignant cells. Their utility in disease 
monitoring and their prognostic value have been demonstrated; for 
example, exosomal miR-301a was found to be up-regulated in the 
serum of GBM patients compared to in healthy controls. Furthermore, 
expression of this miRNA decreased after surgery and increased 
again during relapse in the serum of GBM patients, proving its 
usefulness in monitoring the disease [180].   
Another medical advantage of these small vesicles is the possibility to 
use them for delivering therapeutic molecules. It has been shown that 
treatment with exosomes carrying a cargo of chemotherapeutics was 
more efficient and had fewer side effects than the common way of 
administrating therapeutic agents [181]. Due to their small size, 
exosomes can also get through the blood brain barrier (BBB) [182], an 
advantage in brain tumour therapy. Furthermore, EVs have the 
potential to be used in immunotherapy for the treatment of different 
types of cancers. A clinical study was performed with exosomes 
derived from dendritic cells, which were pulsed with MAGE3 peptides 
and used for the immunization of stage III/IV melanoma patients with 
promising results [183]. The use of exosomes as delivery vectors of 
siRNAs were also shown [184], as well as their capability in delivering 
miRNAs. Evidence for this comes from a study where the most 
abundant miRNA in brain, miR-124 [185], was delivered by exosomes 
and promoted neurogenesis after ischemia in mice [186]. 
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1.6. Paediatric GBM 
1.6.1. Disease and epidemiology
GBM is a high grade brain tumour, with very poor survival outcome. 
GBMs can be either primary or secondary tumours. Secondary GBMs 
arise from lower grade gliomas and they show molecular differences 
from primary GBMs [187]. GBM is the most common tumour of the 
central nervous system (CNS) in adults. In paediatric patients the 
incidence is lower than in adult patients; however due to their 
aggressive clinical behaviour, they cause significant mortality and 
morbidity among children with brain tumours [188]. 
The incidence of GBM is approximatively 3 in 100,000 people per year 
(in the US), more frequent in males than females [189]. It can occur at 
any time during life, though the incidence increases with age [190]. In 
children the incidence of high-grade brain tumours is 0.85 in 100,000 
people of which 3-15 % are GBM [188, 190]. Glioblastomas in children 
can result from a background of cancer predisposition syndromes as 
for example Li Fraumeni Syndrome or be caused by biallelic mismatch 
repair deficiency (bMMRD), however most of the time the tumour is 
sporadic [191, 192]. 
Traditional classification of brain tumours has been done based on 
histopathological analyses. For example, in the 2007 World Health 
Organization (WHO) Classification of Tumours of the Central Nervous 
System, all tumours with an astrocytic phenotype where grouped 
together even if they showed different clinical features [193]. 
Nowadays the molecular based classifications are gaining more focus, 
since they can offer a more precise diagnosis. The newest 
classification of central nervous system tumours by WHO (from 2016) 
incorporates, in addition to the histopathological methods, also 
molecular specifications [194]. Based on this classification, 
glioblastomas are divided into IDH wild type and IDH mutant 
categories with a third group termed glioblastomas NOS (not 
otherwise specified) for tumours without a full IDH status evaluation.  
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Most paediatric brain tumours are supratentorial but they can arise 
also in the cerebellum, brainstem, ventricles, spinal cord, suprasellar 
region, or cranial nerves. At least half of the CNS tumours in children 
are gliomas; most often low grade gliomas (LGG) such as pilocytic 
astrocytomas and embryonal tumours. Medulloblastomas are the most 
common embryonal tumours. Paediatric high grade gliomas (pHGG) 
are mostly glioblastoma (WHO grade IV tumours), but can also be 
diffuse midline glioma and anaplastic astrocytoma [195]. The pHGG 
most often arise in the cerebral hemispheres, but can also originate in 
the thalamus, brainstem, cerebellum, or spinal cord [195].  
1.6.2. Genetics and epigenetics of GBM 
In GBM several signalling pathways are altered, the receptor tyrosine 
kinase (RTK) pathway being one of those. RTKs bind growth factors 
(GFs) and the epidermal growth factor receptor (EGFR) is frequently 
mutated or amplified in GBM [196]. EGFR signalling has important 
functions in brain cell proliferation, differentiation and survival [197]. 
The most common mutation of this receptor is EGFRvIII which results 
in constant activation of this signalling [198]. Aberrations in the 
Ras/MAPK pathway can cause abnormal cell proliferation and 
invasion, and is also commonly altered in GBM, either by mutations in 
RAS or by activation through EGFR [199]. Activated Ras can lead to 
MAPK activation and also affect another pathway, the 
PI3K/PTEN/Akt/mTOR pathway. Here, growth factors with their 
receptors, such as for example EGFR, activate PI3K, which will further 
activate Akt leading to the activation of mTOR which is involved in cell 
growth [200]. PTEN is a tumour suppressor that can inhibit this 
pathway; however PTEN is frequently mutated or deleted in GBM 
[198]. The p53 pathway is frequently mutated, in primary GBMs less 
frequently than in secondary GBMs [200]. Another deregulated 
pathway in GBM is the tumour suppressor pRB pathway, where pRB 
has a crucial role in inhibiting cell cycle progression [200]. 
Genetic alterations can lead to aberrant signalling pathways and in 
GBM these alterations are frequent. The Cancer Genome Atlas 
Project has catalogued genomic aberrations in GBM [198] and based 
on genetic profiles GBM can be divided into four groups: 1) the 
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classical type characterised by multiple copies of EGFR, 2) the pro-
neural type with mutations in TP53, PDGFRA, and IDH1, 3) the 
mesenchymal type with mutations in the NF1 gene, and 4) the neural 
type which shows features of normal cells [201].  
Several studies also revealed heterogeneity among GBM as well as 
diversity between those that arise in children and adults [202]. 
According to a study by Paugh et al. from 2010, pHGG have minimal 
copy number changes compared to those in adults and do not have 
IDH1 hotspot mutations. Furthermore, pHGG exhibit PDGFRA 
amplification and more frequent gain of chromosome arm 1q than 
tumours in adult patients.  The gain of chromosome arm 7q and loss 
of 10q is more frequent in adult than pHGG [203]. Another study 
showed that mutations in the genes coding for H3.3 are very specific 
to and frequent in GBM that arise in children and young adolescence 
[204].  
Incorporation of epigenetic profiles has further divided tumours into six 
subgroups: IDH, K27, G34, RTK I, mesenchymal subtype, and RTK II 
(with their main characteristics presented in Table 1) [202]. These six 
epigenetic subgroups are also delimited based on their genome-wide 
DNA methylation profile [202]. Based on the DNA methylation profile, 
the IDH subgroup showed genome-wide hypermethylation and in 
contrast to this, the G34 subgroup exhibited global hypomethylation 
[202].   
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Table 1. Epigenetic and genetic subgroups of GBM with their main characteristics. 
Adapted from [202]. 
Epigenetic 
subgroup 
Mutations CNV Gene 
Expression 
TCGA 
Age groups 
(age range) 
IDH IDH1, TP53 Proneural Younger adults 
13-71
K27 H3F3AmutK27, 
TP53 
Proneural Childhood 
5-23
G34 H3F3AmutG34, 
TP53 
Mixed Adolescent 
9-42
RTK I Amplification: 
PDFRA 
Deletion: 
CDKN2A 
Proneural Paediatric/Adult 
8-74
Mesenchymal low Mesenchymal Paediatric/Adult 
2-85
RTKII Amplification: 
EGFR 
Deletion: 
CDKN2A 
Classical Older adult 
36-81
In GBM, MGMT methylation status is well studied. This gene encodes 
a DNA repair enzyme, O6-methylguanine methyltransferase, which is 
responsible for removing alkyl groups from the guanine O-6 position. 
In many GBM tumours, the promoter region of this gene is 
hypermethylated leading to silencing of the MGMT gene [205]. Studies 
have shown that GBM patients with hypermethylated MGMT 
promoters responded better to chemotherapy using temozolomide 
(TMZ) and had better outcome than patients where the MGMT is 
expressed [206, 207]. MGMT methylation is therefore used as a 
prognostic marker for therapy response especially in GBM patients 
older than 60 years of age [206, 208]. 
An important part of tumour epigenetics is deregulation of miRNA 
expression. The majority of deregulated miRNAs are overexpressed in 
GBM compared to normal brain tissue [209]. Deregulated expression 
of miRNAs can result from deletions or amplifications at the genomic 
level as has been described for miR-25, miR-26, miR-495, miR-1286, 
and miR-4484 [210]. Furthermore, expression of several miRNAs such 
as miR-124, miR-148a, miR17, miR-30c, miR200a, miR217, and miR-
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265-5p has been shown to be regulated by their DNA sequence
methylation status in adult GSCs [211].
The miRNAs can have different roles in GBM biology. They can be 
involved in tumour suppression, such as for example miR-34a that 
suppresses tumour growth by targeting Notch [212], while let-7a 
silences K-ras and reduces malignancy [213]. Proliferation of GBM 
cells can be influenced by the down-regulation of tumour suppressor 
miRNAs such as miR-491, miR-218, miR-219-5p, and many others 
[214-216]. OncomiRs are a group of miRNAs with tumour growth 
promoting features, and they are known to be overexpressed in 
GBMs. The oncomiRs miR-21, miR-23a, and miR-26a have been 
demonstrated to down-regulate PTEN in glioma cell lines [217, 218]. 
In pHGG tissue several miRNA clusters were found to be up-regulated 
compared to in adult glioma or normal samples. Among these were 
the oncogenic miR-17∼92 cluster members miR-195 and miR-497 
[63]. 
MiRNAs are also involved in chemo and radiotherapy response, such 
as for example miR-132 [219], miR-20a [220], and miR-497 [221]. 
Furthermore, miRNAs with accurate prognostic value have been 
identified: miR-7, miR-124a, miR-129, miR-139, miR-218 (which were 
downregulated), miR-15b and miR-21(which were up-regulated) [222]. 
1.6.3. CSC role in GBM 
GBM tumours are built up by a heterogeneous cell population and the 
cell of origin is still controversial. Some studies claim that astrocytes 
[223] or oligodendrocyte precursor cells [224, 225] that undergo
malignant transformation could be cells of origins. The presence of
CSCs in brain tumours was described for the first time by Singh et al.
in 2004, when they succeeded to isolate a cell population that
expressed CD133 and presented with stem cell properties including
the ability to initiate tumours in vivo [98]. Since then, several studies
have investigated and confirmed the presence of CSCs in brain
tumours with evidence of these cells’ role in tumourigenesis and in
tumour progression. The presence of CSCs in paediatric brain
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tumours, including medulloblastomas and gliomas, has also been 
described [226].   
GSCs share common features with normal NSCs such as the 
expression of certain cell surface markers, transcription factors, and 
structural proteins. GSCs frequently show expression of SOX2 [226] 
OLIG2 [227], NANOG [228], MYC [229], MUSASH-1, BMI-1 [226], the 
neural progenitor/stem cell marker Nestin [230], and the epithelial-
mesenchymal transition (EMT) marker Vimentin [231]. A property of 
CSCs is that they should be able to respond to differentiation cues 
(which can be either withdrawal of growth factors, or addition of serum 
or bone morphogenic proteins) [101]. The differentiated GSCs show 
decreased expression of NSC markers and increased expression of 
the neuronal markers GFAP, MAP2 or TUJ1 [101, 102].  
CSCs show a higher resistance to traditional treatments than the other 
more rapidly cycling cells of the tumour [232, 233]. GSCs are 
considered to be the main players in treatment resistance and relapse 
of GBM [232]. The majority of conventional chemotherapies are 
designed to target fast proliferating cancer cells. However, CSCs are 
slower cycling cells [90] and therefore have the capability to escape 
these treatments and lead to relapse as shown in the graphical 
representation in figure 8.     
 GSC involvement in conventional chemotherapy/radiotherapy Figure 8.
response. These cells are resistant to many of conventional chemo- and 
radiotherapies, leading to relapse. 
Several signalling pathways are also involved in the GSC response 
mechanism to conventional treatments. In a study, Bao et al. showed 
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that GSCs that express CD133 can activate DNA damage 
checkpoints, as well as repair radiation induced DNA damage [233].  
1.6.4. Exosomes role in GBM 
Glioma cells, like many other cells, secrete EVs such as exosomes. 
The first report on exosomes secreted by GBM cells was published by 
Skog et al. who showed that these vesicles, through their RNA and 
protein content, promote tumour growth, and could furthermore be 
used as diagnostic biomarkers [142]. In that study, 4,700 transcripts 
were exclusively found in vesicles but not in the originating cells, 
suggesting a selective sorting process into the exosomes. The most 
abundant genes in the exosomes were shown to be involved in 
biological processes such as cell proliferation, cell migration, and 
angiogenesis. The study also provided experimental evidence that 
RNA delivered by glioma exosomes were translated into proteins 
[142].  
An important step during invasion is angiogenesis, to ensure access 
to nutrients. Studies have shown that GBM exosomes contain 
angiogenic factors such as miRNAs, mRNAs, proteins, and 
extracellular proteases necessary for migration, differentiation, 
proliferation, and progression [234-236].   
A detailed characterisation of the RNA repertoire in the extracellular 
vesicles secreted by GSC identified small RNA enrichments as 
miRNAs [237]. Furthermore, tRNAs, Y RNA, and fragmented mRNAs 
were detected in these vesicles. Very little is known about the average 
copy number of the different RNA species per vesicles and this study 
points to a very low number of transcripts that might influence the 
studies aimed to investigate the functional effect of these vesicles 
[237]. One study describes an exosomal miRNA signature specific for 
phenotypically diverse subpopulations of GSCs [238]. A direct 
visualisation of extracellular vesicles released by glioma cells and their 
up-take by microglia and macrophages in mouse brain supports these 
vesicles’ functional effect on their environment through their molecular 
content delivery [239]. The functional effect of the exosomal content 
was also described in a study where glioma extracellular vesicles 
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delivered and induced gene expression changes in the receiver 
endothelial cells [240]. 
Since these small vesicles have the property to mirror their originating 
cells, several studies have investigated the use of extracellular 
vesicles in medical diagnostics and prognostics [241, 242]. Among the 
exosomal content, DNA [243], miRNA [244] and other small non-
coding RNAs [170], mRNA [142, 245], and protein [246, 247] have 
been used. EGFRvIII in exosomes secreted by glioma cells was 
detected in serum from glioma patients but not from healthy donors 
[142]. MiR-21, a key player in GBM [248], also has diagnostic value; it 
was found to have higher expression in exosomes found in blood and 
cerebrospinal fluid from GBM patients than in the ones from healthy 
subjects [142, 249]. Exosomes were found to be good tools in the 
prediction of drug response in GBM patients through the MGMT gene 
levels detectable in these vesicles [250].   
The involvement of EVs such as exosomes in GBM resistance to 
treatments as well as their use as a treatment delivery system has 
been investigated by several studies [251, 252]. A study with U87 
glioma cells showed that exogenous miR-124 delivered by MSC 
exosomes decreased proliferation and migration of glioma cells and 
also enhanced sensitivity to TMZ [253]. Another study showed similar 
results and pointed out the possible use of MSC for producing 
exosomes with miR-124 as treatment for GBM [254]. The mRNA 
levels found in GSC exosomes accurately reflected the cells profile of 
TMZ resistance related gene expression, such as MGMT, TGM2, and 
NESTIN [255], suggesting these vesicles possible use as biomarkers. 
Exosomal miR-221 was found to be involved in glioma progression 
and TMZ resistance by targeting DNM3 based on a study with glioma 
cell lines [256]. Exosomes with PTPRZ1–MET fusion oncogenes, 
derived from GBM cells, induced EMT in human astrocytes and 
contributed to TMZ resistance, cell migration, invasion, angiogenesis, 
and neurosphere formation [257].  
Despite the extensive amount of studies on GBM exosomes, scant 
information exists on these vesicles’ role in paediatric gliomas, 
especially those secreted by GSCs.  
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1.6.5. Therapy and treatment in GBM 
Maximal safe surgical resection of the tumour is important, however 
due to the infiltrating behaviour of GBM cells, all tumour cells cannot 
be removed. Concomitant and adjuvant treatment with TMZ and 
radiotherapy is also part of the treatment [258]. TMZ is the most often 
used chemotherapeutic agent against GBM. TMZ can 
alkylate/methylate DNA, which may cause DNA damage. This will lead 
to cell cycle arrest in the G2/M phase, ultimately resulting in apoptosis 
[259]. However, the DNA damage can also be repaired by an enzyme 
encoded by the MGMT gene, therefore patients with no or low 
expression of MGMT benefit from TMZ treatment [206]. In parallel with 
the daily TMZ treatment, patients also receive external beam radiation 
therapy [260]. Nevertheless, the tumour will eventually regrow; re-
operation is not always an option, and new chemotherapy and 
irradiation can have toxicity concerns [258]. The use of 
chemotherapeutical agents and irradiation in paediatric patients is 
applied with consideration to the possible negative late effects on the 
developing brain [261]. The use of radiotherapy is recommended 
mostly in children above the age of three to avoid severe adverse 
neurocognitive effects [188]. In adult patients the use of chemotherapy 
is an integral part of GBM treatment. In paediatric patients, similar 
management is used. The efficacy of TMZ for GBM treatment was 
demonstrated in adult patients [260] but not in children [262]. TMZ 
treatment showed a better response in adult patients with methylated 
MGMT and since in pHGG MGMT promoter methylation is less 
frequent, this might be a reason for the lower response [263]. Present 
studies are investigating possibilities how to sensitise paediatric 
gliomas to TMZ, one of them being through therapeutic inactivation of 
MGMT [264].   
Several new treatment options are investigated, such as the use of 
immunotherapy, targeted therapies, and epigenetic drugs. Targeted 
therapies target tumour growth factor receptors, cell cycle regulation, 
angiogenesis, antitumour immune response, and several pathways 
involved in tumour biology. Some of these treatments are used in 
pHGG management, such as Bevacizumab which is an angiogenesis 
inhibitor against VEGFA [263]. The two most well-known classes of 
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epigenetic drugs are HDAC inhibitors and those that target DNMTs. 
Over the years, many clinical and preclinical studies have investigated 
the effect of epigenetic drugs in different types of cancers. In brain 
tumours, some of these epigenetic drugs are or have been 
investigated in clinical trials, also as part of a combination therapy. 
Valproic acid, Vorinostat, Belinostat, and Romidepsin are among 
those [125].  
These diverse approaches and several clinical trials in the field of 
GBM indicate the possibility in the future to find more efficient therapy 
for these patients. 

OBJECTIVES 
2 
"Don't let anyone rob you of your imagination, your creativity, or your 
curiosity." 
Mae Jemison 
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The overall aim of this thesis was to gain more insights into the 
epigenetic mechanisms and their role in GSCs derived from paediatric 
patients, for a better understanding of the biological processes in brain 
tumours. This knowledge provides a foundation for more efficient 
treatment designs for paediatric GBM patients in the future.  
Specific aims: 
Study I 
• Investigate the miRNA repertoire of GSCs and NSCs.
• Explore the miRNA content of the exosomes released
by these cells.
• Study the GSC exosomes’ effect through their miRNA
content on NSCs.
Study II 
• Explore the epigenetic interplay between miRNA
expression and their DNA methylation in GSCs.
• Investigate the role of miR-497-5p in mediating
treatment response against TMZ in GSCs.

MATERIALS AND METHODS 
3 
 “Just remember, there's a right way and a wrong way to do everything 
and the wrong way is to keep trying to make everybody else do it the 
right way.” 
Harry Morgan – M*A*S*H 

Ágota Tűzesi 
37 
3.1 Cells 
3.1.1 Patient materials 
For the studies included in this thesis patient-derived primary cell lines 
established from the high-grade paediatric gliomas were used [102]. 
Regional ethical approval was obtained for the studies (Dnr 604-12).  
3.1.2. Cells and cell cultures 
Patient-derived primary cell lines have the great advantage that they 
maintain the originating tumour features in comparison with 
commercial cell lines which have acquired mutations and 
chromosomal aberrations during a long culturing time. The cell lines 
were enriched for stem cells by growing the cells in stem cell media 
DMEM-F12 supplemented with B27 (Gibco), N2 (Gibco), EGF (20 
ng/ml, Peprotech) and in some cases FGF-2 (20 ng/ml). To gain 
adherent cultures, the culturing flasks/plates were coated with laminin 
(Sigma or BioLamina).  
The following six GSC lines were used: GU-pBT-7, GU-pBT-10, GU-
pBT-15, GU-pBT-19, GU-pBT-23, and GU-pBT-28. All cell lines were 
characterised for stemness in a previous study by stem cell markers 
expression, differentiation properties, and tumour initiating potential in 
vivo [102, 104]. Furthermore, DNA mutations, CNV and DNA 
methylation patterns were described for these cell lines [102]. All 
samples are IDH1 and IDH2 wild type.  
For the authentication of the established cell lines short tandem repeat 
(STR) profiling was used.  
The NSC lines used in these studies; NS-1, NS-4, and NS-5 have 
previously been described and characterised [265]. 
Cell culture media was changed every 4th or 5th day and all cell 
cultures were confirmed negative for mycoplasma contamination.  
For Study I media was collected from each cell line for exosome 
isolation, as described below.  
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For functional experiments 5-7,000 cells/well in 96-well plates or 
4x104-1x105/well in 24-well plates was used.  
3.1.3. Drug treatments 
In Study II cells were treated with TMZ (Selleckchem, S1237) to 
investigate GSC response to the most frequently used 
chemotherapeutical drug in GBM treatment. TMZ cytotoxic effect 
results from the addition of methyl groups on the DNA nucleotides, 
specifically to adenosines on O3 and guanines on N7 and O6 sites. 
During DNA replication the added methyl group on the guanines O6 
sites will result in the insertion of a thymine instead cytosine and this 
will lead to cell death [259]. For these experiments, 600 µM TMZ was 
added to the cells every day, for 3 days followed by 
immunocytochemical analysis to evaluate the effect on number of 
cells, viability and proliferation. 
To study if miRNA expression was dependent on DNA methylation 
status in Study II, the cells were treated with Decitabine (Selleckchem, 
S1200). Decitabine, also known as 5-aza-2’-deoxycytidine, is a 
cytidine analogue which is incorporated into the DNA during DNA 
synthesis and by this interrupts the interaction with DNMTs. This will 
lead to DNMT degradation resulting in the lack of methylation of 
cytosine [266]. Cells were treated with 500 μM Decitabine every day 
for four days followed by gene expression analysis to investigate if the 
expression of the miRNA of interest was affected by the DNA 
methylation changes.  
3.1.4. Transfection with siRNA and CRISPR 
In Study II synthetic siRNA inhibitors were used for the silencing and 
synthetic mimics for overexpression of the studied miRNAs. 
Transfection with 4D-Nucleofector System was used to deliver the 
synthetic siRNAs to the cells. All control samples were transfected 
with negative control siRNAs, to distinguish between specific activity 
given by inhibitor/mimic and background effects. The negative control 
mimics/inhibitors used have minimal sequence identity with human 
miRNAs. 1x105 cells were transfected and seeded. At 24 h post 
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transfection the cell culture media was changed or cells were collected 
for RNA extraction.  
Since the expression of miR-497-5p was very high in GSCs and the 
silencing with siRNA does not have a lasting effect necessary for 
functional studies, a more long-term method was used; knock-out 
using CRISPR constructs. Guide RNA (gRNA) was designed with the 
Benchling web site (https://benchling.com/crispr), using a scoring 
system developed by Doench et al. [267]. For the transfection of the 
cells, a ribonucleoprotein (RNP) complex was prepared according to 
the manufacturer’s instructions. These RNP complexes were 
transfected into the cells through electroporation with the 4D 
Nucleofection System (Lonza). Controls were transfected with a non-
targeting crRNA. The effect of knock-out was investigated based on 
the miR-497-5p expression at 72 hours post transfection. For the 
knock-out functional effect, the cells were seeded in a 96 well plate 
and treated with TMZ for 3 days followed by immunocytochemistry 
studies.    
3.2 Exosomes 
3.2.1 Exosomes isolation 
In Study I, exosomes isolated from cell culture media were used for 
miRNA profiling and for functional studies. 
For this purpose, the golden standard exosome isolation method was 
used; differential centrifugation. This is the most widely used method 
for EVs isolation from cell culture media [268]. The method principle is 
to use several numbers of centrifugation steps with different speed 
and time. The aim is to pellet the diverse sized/density particles from 
the media, starting with a shorter and slower centrifugation speed that 
will pellet the cell contaminations. The pellet from this step is 
eliminated and the supernatant will be centrifuged at a higher sped to 
eliminate apoptotic bodies, followed by ultracentrifugation with Ti70 
fixed-angel rotor (Optima L-90 K Beckman Coulter). 
Ultracentrifugation is necessary to pellet smaller vesicles. A shorter 
time of 30 minutes and a slower speed of 28,000 x g (19,400 rpm) are 
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used to pellet microvesicles. A filtration step with a 0.22 μm filter is 
included followed by a final step of ultracentrifugation at a higher 
speed and longer time to isolate the smallest EVs; the exosomes. 
Based on previous studies, the time and speed of ultracentrifugation 
can influence the exosomal RNA yield [269]; therefore a two hour at 
118,000 x g (40,000 rpm) was used for this step. The used isolation 
steps are represented in Figure 9. The exosome pellets were re-
suspended in PBS and kept at -80oC for further processing. 
 Exosome isolation steps where the cell culture media first is Figure 9.
centrifuged at a slower speed to pellet cell debris, followed by a higher speed 
to pellet ABs. The next step of centrifugation will result in pelleting MVs, 
followed by the supernatant filtration and centrifugation at a higher speed 
during 2h. The resulting pellet contains the exosomes.
3.2.2 Exosomes characterisation 
In order to characterise the isolated vesicles three different methods 
were used which confirmed exosome features. 
One of the methods to characterise the isolated vesicles as exosomes 
is to show that these vesicles contain the most common exosomal 
proteins. This can be achieved with Western blot analysis with 
antibodies against the most common exosome markers, CD81 and 
Ágota Tűzesi 
41 
CD9. In parallel, the presence/absence of Calnexin, an endoplasmic 
reticulum marker was investigated. Calnexin can be detected in cell 
samples and other EVs but not commonly in exosomes. Protein 
extracted from these vesicles was used for the Western blot analysis.  
A second characterisation of the isolated vesicles was based on their 
size. For this a nanoparticle tracking analysis device termed Zeta View 
(Particle Matrix, Germany) was used. The principle of this method is 
based on the Brownian motion of the particles, in this case the 
vesicles. The different sized vesicles have different diffusion 
movements in the re-suspended liquid and based on this the 
hydrodynamic diameter of each vesicle is determined.  
A third characterisation method for the isolated vesicle was based on 
their shape and size. For this transmission electron microscopy (TEM) 
was used that is capable to visualise these small vesicles.  
3.2.3 Treatment of cells with exosomes 
To study the effect of exosomes secreted by GSCs on NSCs (Study I), 
these vesicles were isolated with differential centrifugation as 
previously described, and added to NSCs. The exosome 
concentration was measured with BCA Protein Assay (ThermoFisher) 
on Wallac 1420 multilabel counter (Perkin Elmer). A total of 30 µg/ml 
GSC exosomes were added every day for 8 days to NSCs, control 
samples were treated in the same way but with NSC-derived 
exosomes. At the end of the experiments exosome treated cells were 
collected for RNA isolation. 
3.3 Molecular biology methods 
3.3.1 RNA extraction, qRT-PCR for miRNA and gene 
expression studies 
In Study I the RNA extraction from cells and exosomes was done with 
QIAzol (Qiagen) according to the manufacturer’s protocol, with the 
addition of Glycogen (Invitrogen) to increase the RNA yield. The RNA 
extracted from cells was treated with TURBO DNase (Invitrogen) and 
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enriched in small RNA fraction with RNA Clean & Concentrator™-5 
(Zymo Research).  
In Study II total RNA extraction was performed with Direct-zol™ RNA 
MiniPrep, (R2052, Zymo research) according to the manufacturer’s 
protocol. 
RNA was quantified with Qubit RNA HS Assay Kit (Invitrogen) in both 
studies. 
The isolated RNA from exosomes and cells (Study I) were used for 
miRNA array and the array data validation with quantitative real-time 
PCR (qRT-PCR). Furthermore, the RNA isolated from cells treated 
with exosomes, were used for TaqMan Low Density Array (TLDA) 
cards. The detailed descriptions of the two types of arrays are 
presented in the following subchapter. For the qRT-PCR (used for the 
miRNA array results validation) the miRCURY LNA™ Universal RT 
microRNA PCR, Starter Kit with validated primer sets (Exiqon, 
Denmark) was used and ABI 7500 FAST Real-Time PCR System. For 
the reverse transcription 20ng of total RNA from exosomes or small 
RNA enriched from cell samples were used. UniSp6 RNA Spike-in 
template was added to each sample and used for normalization.  
In Study II for the relative quantification of miRNAs the TaqMan Single 
Tube Assays were used and ABI 7500 FAST Real-Time PCR System. 
First, cDNA was synthetized with specific RT primers and TaqMan 
Small RNA TaqMan™ MicroRNA Reverse Transcription Kit followed 
by qPCR performed with TaqMan™ Universal Master Mix II, with UNG 
according to the manufacturer’s protocol (Thermofisher). For 
normalisation the miR-92-a was used.  
For gene expression analysis (Study II), cDNA synthesis was 
performed with SuperScript™ III Reverse Transcriptase (Invitrogen) 
followed by qPCR performed by using GoTaq qPCR Master Mix 
(Promega). For ∆CT calculations GAPDH was used as a reference 
gene.  
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3.3.2 MicroRNA array and TLDA cards (Study I) 
To characterise and quantify the miRNA content of the exosomes and 
their originating cells, a platform with several benefits compared to 
others found on the market was used, the 3D-Gene Human miRNA 
Oligo chip ver.21 (Toray Industries). This array detects as many as 
2,565 miRNA transcripts. Another benefit of this array is the low 
amount of RNA input that is required (100ng). The RNA is directly 
hybridized to beads and the intensity of each miRNA is measured and 
analysed with the 3D-Gene Scanner 3000 (Toray), according to the 
manufacturer’s instructions. The data was normalized using miRNA 
“spots” with background subtracted data.  
For the functional study of the exosomes’ effect on NSCs, TLDA cards 
were used. These cards were custom made, examining 192 genes in 
duplicates. The genes were selected based on that they were either 
predicted or experimentally validated target genes of the GSC 
exosomal miRNAs or have roles in cell cycle, stemness, 
differentiation, glioma genesis, or neurogenesis. For cDNA synthesis 
the High- Capacity RNA-to-cDNA Kit (Applied Biosystems) was used. 
In total, 10-15ng of cDNA was loaded per port on TaqMan Custom 
Arrays (Applied Biosystems) and run on a Viia7 Real-Time PCR 
system (Applied Biosystems) according to the manufacturer’s 
instructions. GAPDH was used as reference gene for ∆CT 
calculations. 
3.3.3 Immunocytochemistry 
In Study I for the exosomes up-take by cells the PKH67 Green 
Fluorescent Cell Linker for General Cell Membrane Labelling (Sigma-
Aldrich) was used to stain the GSC secreted exosomes that were 
added to NSCs. The cells were stained with mouse monoclonal Nestin 
(R&D MAB1259), 1:500 and DAPI was used as a nuclear 
counterstain. Confocal imaging (LSM 700 Carl Zeiss microscope) was 
used for the visualisation of the exosome up-take by cells.  
In study II for the assessment of the cells response towards TMZ with 
or without the miR-497-5p or miR-195-5p overexpression/silencing the 
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LIVE/DEAD™ Cell Imaging Kit (488/570; Thermofisher) and Hoechst 
(1:2000; Thermofisher) was used. In case of cell proliferation studies 
EdU staining (Thermofisher) and DAPI as a nuclear counterstain, 
according to the manufacturer’s instructions were used. Image 
acquisition of the cells was performed with Operetta High-Content 
Imaging System and the data processing with Harmony software 
(Perkin Elmer). 
3.3.4 DNA methylation profiling 
In Study II the used DNA methylation data set previously was 
generated [102] using the Infinium Human Methylation 450K 
BeadChips (Illumina). This array identifies the methylation levels of 
more than 450,000 CpG sites. These CpG sites are distributed across 
the genome and cover most coding and non-coding genes and also 
regulatory regions such as enhancers. The CpG sites are further 
annotated to different genomic features such as CpG islands, shores, 
shelves and open-sea. Important to note is that the bisulfite-
modification of DNA which is performed prior to hybridisation to the 
arrays, do not distinguish between 5-methylcytosine and 5-
hydroxymethylcytosine. Hence, the CpG sites identified as 
differentially methylated could have either of these methylation forms.   
3.4 Data analysis and interpretation 
3.4.1 Statistics and bioinformatics 
In Study I for the validation of miRNA array with qRT-PCR, Pearson 
correlation between the miRNAs relative quantities was used and 
standard error was calculated.  
The microarray data in Study I was mainly analysed with GenEx 
analysis software (MultiD Analyses). Differentially expressed miRNAs 
between cell and exosome samples were identified with R/package 
limma. Hierarchical clustering was applied to all miRNAs for the 
visualisation of differentially expressed miRNAs, using Euclidean 
distance metric and average linkage. In order to elucidate why some 
miRNAs had higher intensities in exosomes than in cells, similarities in 
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their sequences were searched for. The online application, Improbizer 
(https://users.soe.ucsc.edu/~kent/improbizer/improbizer.html) was 
used. All miRNAs included on the array were used as background. 
Clustering of the miRNA sequences was done with ClustalW, default 
settings, using the R package msa and visualized with the R package 
ape. 
For the TLDA analysis (Study I), ∆CT was calculated using GAPDH as 
reference gene. Hierarchical clustering was performed using 
Euclidean distance metric and average linkage. The ∆∆CT-values 
were calculated between non-treated and GSC exosome treated, 
between NSC exosome and GSC exosome treated cells to estimate 
Gaussian distribution. This was used to determine differentially 
expressed genes based on the mean ± 1.96*(standard deviation). 
In Study II the genomic position of the miRNAs detected by the 
microarray were mapped to the genomic position of the CpG sites 
included on the 450K methylation arrays (data obtained from previous 
studies). In this analysis all sites located at most 1,600 base pairs (bp) 
upstream or downstream of the DNA sequences coding for the 
miRNAs were included. The focus of this data analysis was the 
relationship between methylation and miRNA expression, therefore 
only miRNAs that had at least one associated measured CpG were 
included, and those miRNAs that were detected in all cell samples. 
Pearson (pairwise) correlations between the expression of each 
miRNA and the methylation levels of all the adjacent CpG sites were 
calculated. High correlations created by one single outlier sample 
were excluded, as well as high correlations from pairs where the 
maximum difference in beta-value between two samples was below 
0.2.  
For Study II, public DNA methylation data sets were downloaded from 
NCBI GEO database, accession numbers: GSE36278 and 
GSE52556. In the two datasets the total number of samples was (after 
removal of irrelevant samples) 78. From this 51 were paediatric GBM 
and 27 were control tissue (13 foetal and 14 paediatric). The purpose 
of the analysis of these data sets was to explore the miR-497-5p and 
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miR-195-5p DNA methylation patterns in a bigger sample cohort, than 
in the used cell lines. For the identification of the differences in Beta 
level for the two CpG sites between the two groups (normal and 
cancerous) two-sample t-test was applied.  
All experiments in Study II were performed in at least technical 
triplicates. Most of the experiments, as in case of the miRNAs 
expression, target genes expression, the miRNAs effect on cell 
number and response to TMZ were performed in biological triplicates, 
each with three technical replicates. To establish statistically 
significant differences the t-Test: Two-Sample Assuming Equal 
Variances was applied and p values <0.05 were considered 
statistically significant. 
3.4.2 Pathway analysis and network buildings 
In order to gain more knowledge of the miRNAs role, in Study I 
pathways enriched with miRNA target genes based on Kyoto 
Encyclopedia of Genes and Genomes (KEGG pathways) were 
explored with the use of the DIANA TOOLS mirPath v3 software. The 
micro-T-CDS algorithm predicts miRNA targets in CDS or 3’-UTR 
regions while Tarbase uses validated miRNA targets [270]. Based on 
these two tools offered by the DIANA web tool, target networks were 
constructed for miRNAs and target genes with Cytoscape (Version 
3.1.1) for a better visualisation of miRNA and target genes interaction 
[271]. Furthermore, for the target genes involvement in biological 
processes, the DAVID web tool was used with the GO BP_ALL 
settings [272]. 
RESULTS AND DISCUSSION 
4 
"I was taught that the way of progress was neither swift nor easy."
Marie Curie 
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Study I: Exploring the miRNA content of GSC 
exosomes and their role in inducing gene expression 
changes in NSCs 
Several studies have pointed out the differences on a molecular level 
between GBM in children and in adults [203, 204]. Exosomes have 
gained much attention especially in the last decade, since the 
discovery of their molecular content and their involvement in cell to 
cell communication [130]. However, extracellular vesicles from 
paediatric GSCs have not been investigated. Since GSCs are 
considered to be one of the driving forces behind GBM, it is essential 
to investigate these cells’ genetics and epigenetics. Therefore, in this 
study the miRNA content of GSCs isolated from paediatric patients 
was investigated. Furthermore, the miRNA content of the exosomes 
released by these GSCs was explored in detail. Finally, the GSC 
exosomes and their miRNAs effect on NSC gene expression were 
studied.  
Six different primary paediatric glioma stem cell lines were used in this 
study. As controls three neural stem cell lines were used. 
Characterisation of the EVs isolated from the cell culture media based 
on three different methods confirmed their identity as exosomes, 
shown in Figure 10. 
The investigation of miRNA expression in GSCs in comparison with 
NSCs led to the identification of several differentially expressed 
miRNAs. Some of these differentially expressed miRNAs were found 
to be up-regulated in GSCs compared to NSCs. One miRNA 
upregulated in GSCs was miR-497-5p, which has previously been 
associated with brain tumours [63, 273]. High expression of this 
miRNA in the U87 glioma cell line was associated with TMZ resistance 
and was also described to have a higher expression in pHGG than 
adult high grade gliomas or normal tissue [63, 274].   
Epigenetics of paediatric glioma stem cells; focusing on exosomes, miRNAs and DNA 
methylation 
50 
 Experimental set-up and exosome characterisation. A) Six Figure 10.
GSC and three NSC lines were used for RNA extraction and exosome 
isolation from their cell culture media. The RNA extracted from cells and 
exosomes was used for miRNA array to identify differentially expressed 
miRNAs. B) Exosome characterisation with TEM. C) Exosome 
characterization by size. D) Exosome characterization by surface markers. 
Based on their expression level (intensity), the miRNAs clustered the 
cell and exosome samples in two different groups. Several miRNAs 
were found to be expressed just in the cell samples while others were 
expressed only in the exosome samples.  
Forty-two differentially expressed miRNAs were identified between 
GSC and NSC exosomes. Some of them, for example miR-1290 and 
miR-1246, both associated with neural differentiation [275], and were 
up-regulated in GSC exosomes compared to NSC exosomes. These 
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miRNAs have not been described previously in the context of GSC 
exosomes.  
MiRNAs identified to be differentially expressed in exosomes 
originating from GSCs compared to those secreted by NSCs, were 
found to be enriched in cancer related KEGG pathways.  
The identification of a higher number of differentially expressed 
miRNAs in exosomes than in cells was an interesting finding that led 
to further exploration of this phenomenon. Most of these miRNAs were 
up-regulated in exosomes compared to cells (GSC exosomes: 147 
and NSC exosomes: 100 miRNAs). In order to understand why some 
miRNAs have a higher expression in exosomes than in their 
originating cells, investigations of the miRNAs sequences were done. 
Two often repeating sequences were detected in the miRNAs that had 
higher expression in exosomes than in cells. One of these repeating 
patterns in the miRNAs sequence was previously described and 
termed exo motif (GGAG) [149], while the newly identified sequence 
was GGGGC (Figure 11). 
Figure 11. Exo motifs. A) The previously known exo-motif and B) the newly 
detected exo-motif. 
The Villarroya-Beltri et al. study on exo motifs suggested that these 
repeating sequences might play a role in miRNA sorting into 
exosomes [149]. The exact mechanism of RNA sorting into exosomes 
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is yet unknown, however more studies have provided evidence that 
support the existence of such a mechanism [144, 146, 147]. The 
Study I results sustain these miRNA sorting mechanisms hypothesis.   
Some miRNAs with these exo-motifs seem to be present both in 
cancer and normal samples, while some are specific to either group of 
samples. However, some miRNAs with these exo-motifs were 
identified as differentially expressed just in the GSC exosomes but not 
in the case of normal samples. We termed this group of miRNAs 
‘glioma exosome specific’ and most of them were up-regulated in the 
exosomes compared to their originating cells. One could speculate 
that the preferential sorting of the miRNAs into exosomes in cancer 
cells is influenced by malfunctioning cellular mechanisms, resulting in 
the secretion of exosomes with a miRNA content that could play a role 
in the cellular niche tumour transformation.  
Building on the hypothesis that the exosomal content could influence 
surrounding cells, the GSC exosomes effect on NSC gene expression 
was studied. Twenty-three genes were down-regulated while four up-
regulated in the samples treated with GSC exosomes compared to the 
control samples. Some of the down-regulated genes were tumour 
suppressor genes (PTEN, TET3) or genes with a role in stemness, 
differentiation, or cell fate (NOTCH1, NOTCH2, JAG1, DLL1 and 
GFAP) [276, 277]. 
 GSC exosomes effect on NSCs. A) Experimental set-up and B)Figure 12.
the GSC exosomes effect on NSC gene expression. 
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These findings suggest that the GSC exosomes, through their miRNA 
content, are capable of inducing gene expression changes in NSCs 
confirming these small vesicles’ possible role in tumour biology.  
Study II: Epigenetic interplays and their involvement in 
mediating response to chemotherapy in GSCs 
GSCs have an important role in GBM development, maintenance and 
resistance to chemotherapeutical agents such as TMZ. Epigenetic 
modifications are imperative for all cells, including GSCs. However, 
the knowledge on the role of epigenetic mechanisms and their 
potential involvement in GSCs resistance to chemotherapy is scant. 
Thus, in this study DNA methylation and its role in regulating miRNAs 
expression were investigated.    
DNA methylation array and miRNA array data from two previous 
studies [102, 150] of six paediatric GSC and three NSC cultures was 
used to identify correlations between the miRNA expression and their 
DNA methylation. The experimental set-up is shown in figure 13.  
 Experimental set-up for study II. MiRNA and DNA methylation Figure 13.
data was used from six GSC and three NSC lines to identify correlations 
between miRNA expression and their DNA sequence methylation. 
Several miRNAs expression correlated with their DNA sequence 
methylation; negatively or positively. The top miRNA that had a 
negative correlation was miR-497-5p, while miR-195-5p from the 
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same chromosomal region was also found to negatively correlate with 
its DNA sequence methylation. These two miRNAs were identified in 
Study I as up-regulated in GSCs compared to NSCs. These results 
suggest that the miR-497-5p and miR-195-5p high expression in 
GSCs could be a result of the lack of DNA methylation. To further 
support this finding, we used publically available data to obtain a 
larger sample cohort. These data sets confirmed the differential DNA 
methylation of two CpG sites for miR-497-5p and miR-195-5p between 
normal brain and tumour tissue. Additionally, our experiments with the 
DNA methyltransferase inhibitor decitabine confirmed that miR-497-5p 
but not miR-195-5p expression, at least indirectly is regulated by its 
DNA methylation pattern.  
Previous studies using traditional glioma cell lines such as U87 have 
investigated the role of miR-497-5p in TMZ resistance [221, 274]. 
They showed that the high expression of this miRNA decreased cells’ 
sensitivity to TMZ by inhibiting apoptosis [221, 274]. However, another 
study showed that the low expression of miR-497-5p in glioma 
patients is associated with poor prognosis [278]. The miR-497-5p role 
in paediatric GSCs remained unexplored. In several different tumour 
types, high expression of miR-497-5p was associated with decreased 
cell proliferation, therefore it was considered to have tumour 
suppressive properties [279, 280]. These contradictory observations 
from previous studies [278-280] and the findings from the Study I led 
to more detailed investigations of the miR-497-5p and miR-195-5p role 
in GSC response to TMZ. Hence, these miRNAs were overexpressed 
in NSCs and GSCs followed by TMZ treatment for 3 days. 
Immunocytochemistry analysis revealed a decreased cell number and 
cell proliferation when miR-497-5p was overexpressed, but not for 
miR-195-5p overexpression. The TMZ treatment resulted in a higher 
cell number in the samples with overexpressed miR-497-5p than in 
the control samples or those with miR-195-5p overexpressed. This 
suggests the miR-497-5p overexpression, but not miR-195-5p 
overexpression lead to a decreased cell number but also to a lower 
TMZ response both in NSCs and GSCs (graphical representation in 
Figure 14). The lower response to TMZ by the cells with high miR-
497-5p could be due to the slower cell proliferation induced by this
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miRNA. TMZ affects especially fast proliferating cells by inducing cell 
cycle arrest in G2/M phase which lead to apoptosis [259].   
Figure 14. MiR-497-5p expression and its link to GSCs response 
towards TMZ. The overexpression of miR-497-5p in GSCs and NSCs lead to 
decreased cell proliferation and lower sensitivity to TMZ. 
The miR-497-5p has a very high expression in GSCs and the siRNA 
silencing is a transient effect. Therefore, a CRISPR knock-out system 
was used for the miR-497-5p silencing in GSCs used in the functional 
part of the study. The miR-497-5p knockout resulted in the opposite 
effect as the miRNA overexpression; the cell number increased and 
effect of TMZ increased compared to control cells that had been 
transfected with negative guide RNA.  
In order to gain more knowledge about the mechanisms by which 
miR-497-5p influences cell proliferation miRNA target genes were 
investigated. The KCNN4 is a direct target gene of miR-497-5p with a 
role in cell proliferation, while SP9 is a transcription factor [281, 282]. 
Both genes’ expression decreased when the miRNA of interest was 
overexpressed in NSCs. Also, the expression of the genes increased 
when the miR-497-5p was silenced in GSCs. Furthermore, the 
investigation of the mechanism behind the reduced cell proliferation 
rate caused by miR-497-5p overexpression led to the investigation of 
S phase related genes expression. The miR-497-5p overexpression 
resulted in decreased gene expression of three genes involved in 
DNA replication; PCNA, MCM2 and CDT1 [109, 110]. Previous 
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studies have shown that these genes have higher expression in faster 
proliferating cells. Their downregulation resulting from miR-497-5p 
overexpression suggest this miRNA is affecting cell proliferation 
through S phase related genes. Several genes have previously been 
described to have differential expression in fast growing and dormant 
tumour cells [108, 283]. Therefore, several genes characteristic for 
dormant tumour cells were investigated after the miR-497-5p 
overexpression in NSCs or silencing in GSCs. The expression of the 
studied genes (TGF-β2, THSBS-1, EphA5 and IGFBP-5) was affected 
accordingly by the miR-497-5p overexpression and silencing, 
respectively, in NSCs and GSCs. This indicates that miR-497-5p does 
not affect only genes related to cell proliferation but also genes related 
to dormant tumour cells.  
These results suggest that miR-497-5p has a role in cell proliferation; 
affects genes found to be upregulated in dormant tumour cells and 
can be linked to TMZ response.  
CONCLUSIONS 
5 
"I hadn't been aware that there were doors closed to me until I started 
knocking on them." 
Gertrude B. Elion 
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Based on the findings from Study I the following conclusions can be 
drawn: 
• The miRNA profiles differ between NSCs and GSCs as
do the exosomal miRNA content of these cells.
• The number of differentially expressed miRNAs is
higher between exosomes than between the cellular
content of NSCs and GSCs.
• MiRNAs up-regulated in exosomes compared to their
originating cells often contain two repeating
sequences, termed exo-motifs: GGAG and GGGGC
• The GSC exosomes can induce gene expression
changes in receiver NSCs.
From Study II the following can be concluded: 
• The miR-497-5p expression is indirectly regulated by
DNA methylation.
• Overexpression of miR-497-5p, but not miR-195-5p,
results in a reduction of cell number in GSCs and
NSCs.
• MiR-497-5p, but not miR-195-5p, overexpression
results in a lower response to TMZ in NSCs and
GSCs.
• The miR-497-5p induces expression changes in S
phase and genes previously described as dormancy-
related.

FUTURE PERSPECTIVES 
6 
 “It is the brain, the little grey cells on which one must rely. One must
seek the truth within - not without." 
Agatha Christie
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Developing more efficient treatment strategies are vital, as high-grade 
gliomas are incurable. To achieve this, a deep knowledge of the 
driving mechanisms in paediatric GBM is important. CSCs have a 
significant role in GBM and the generation and maintenance of these 
cells are orchestrated by different epigenetic mechanisms.  
The first study in this thesis brings a detailed profiling of the miRNA 
content of GSC exosomes, which has not previously been 
investigated in CSC from paediatric GBM. This shed light on one of 
the possible communication channels of the GSCs. The exosome 
content of other cells from the tumour niche have not been 
investigated, which future studies need to address in order to advance 
our understanding of the cell to cell communication in paediatric GBM. 
Furthermore, the GSC secreted exosomes miRNA profile from Study I 
could serve as a base to identify biomarkers from patient’s blood for 
diagnostic and prognostic purposes.  
Elucidating the reason why GSCs are secreting exosomes with higher 
expression of the miRNAs miR-1290 and miR-1246 (both associated 
with neural differentiation) than NSCs would be an interesting topic to 
investigate. One could speculate that this is due to a mechanism by 
which GSCs try to maintain their stemness. Deciphering the exact 
mechanism of miRNA sorting into exosomes has been investigated 
previously and also in Study I in this thesis, however its complexity 
requires more in depth studies [147, 149, 150]. The understanding of 
these mechanisms could have an important role in understanding why 
some cells are packing up certain miRNAs into exosomes and 
releasing them, especially if this could be a strategy by which cancer 
cells are assuring their invasion success.  
The induced gene expression changes in NSCs by the GSC 
exosomes found in Study I are an example of a functional effect that 
might take place in the niche of the brain cells. Further investigations, 
such as the effect of GSC exosomes on differentiated glioma cells and 
vice versa would be an interesting follow-up study. Also, the validation 
of these results in animal models could lead to more knowledge on the 
role of these vesicles in paediatric GBM biology. 
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The TMZ efficiency in the treatment of children with GBM is lower than 
in adults [262]. This has been linked to the fact that in most of the 
paediatric GBM, the MGMT gene promoter is unmethylated. The 
development of new strategies to sensitise these cells to TMZ are 
ongoing [263]. The second study in this thesis showed that the higher 
expression of miR-497-5p in GSCs compared to NSCs could be due 
to the unmethylated adjacent CpG sites. A question raised based on 
this finding is if restoring methylation would sensitise these cells to 
TMZ. Study II showed that miR-497-5p expression change influenced 
not just the proliferation and response to TMZ but also affected the 
expression of genes that are upregulated in dormant tumour cells. 
These results raise further questions on what is more ideal; GSCs with 
high miR-497-5p that will result in a lower proliferation but worse TMZ 
response or GSCs with low miR-497-5p, higher cell proliferation and 
better response to TMZ. MiR-497-5p was found in a previous study to 
have higher expression in GSCs than in differentiated cells [284], but 
the expression change cause and role is unknown. The evaluation of 
miR-497-5p expression and its DNA methylation in differentiated 
paediatric glioma cells would be an interesting next step. Also, the 
study of miR-497-5p overexpression and silencing in differentiated 
cells and its effect on TMZ response could be complementary to the 
present study. Targeting this miRNA might contribute to a more 
efficient TMZ response in paediatric GBM.  
The two studies of the thesis contribute at some extent to the 
deciphering of epigenetic mechanisms and exosomes involvement in 
GSC biology. However more knowledge on these mechanisms is 
required to better understand paediatric GBM towards a more efficient 
therapy design in the future.  
. 
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